Lipoprotein(a) level is independently correlated with vulnerable plaques in patients with coronary heart disease
CSTR:
Author:
Affiliation:

(Department of Coronary Heart Disease, the First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang 830011, China)

Clc Number:

R541.4

  • Article
  • | |
  • Metrics
  • |
  • Reference [27]
  • |
  • Related
  • |
  • Cited by
  • | |
  • Comments
    Abstract:

    Aim To study the correlation between lipoprotein(a) [Lp(a)] level and coronary vulnerable plaque based on optical coherence tomography (OCT). Methods From January 2015 to August 2018, patients admitted to the Heart Center of the First Affiliated Hospital of Xinjiang Medical University who were diagnosed as coronary heart disease by coronary angiography were examined by OCT. The analysis of the relationship between lipoprotein (a) level and coronary vulnerable plaque were completed by multiple linear regression and other statistical methods. Results A total of 144 patients were enrolled. (1)According to the Lp(a) level, the patients were divided into two groups:Lp(a) ≤300 mg/L group (n=99) and Lp(a) >300 mg/L group (n=45). The lipid arc of plaque in Lp(a) >300 mg/L group was larger than that in Lp(a) ≤300 mg/L group (P=0.021), and the incidence of vulnerable plaque was higher than that in Lp(a) ≤300 mg/L group (P=0.001). (2)The patients were divided into vulnerable plaque group (n=36) and non-vulnerable plaque group (n=108) by OCT. There were significant differences in sex, smoking history, type 2 diabetes mellitus, body mass index, low density lipoprotein and Lp(a) between the two groups (all P<0.05). Multivariate Logistic regression analysis showed that Lp(a), type 2 diabetes mellitus and low density lipoprotein were independent influencing factors of vulnerable plaque, and were predictors of vulnerable plaque occurrence. Conclusion The high level of lipoprotein (a) is independently correlated with coronary vulnerable plaques.

    Reference
    [1] 马丽媛, 吴亚哲, 王文, 等.《中国心血管病报告2017》要点解读.中国心血管杂志, 8,3(1):3-6.
    [2] Khot UN, Khot MB, Bajzer CT, et al.Prevalence of conventional risk factors in patients with coronary heart disease.JAMA, 3,0(7):898-904.
    [3] Greenland P, Knoll MD, Stamler J, et al.Major risk factors as antecedents of fatal and nonfatal coronary heart disease events.JAMA, 3,0(7):891-897.
    [4] Khera AV, Everett BM, Caulfield MP, et al.Lipo-protein(a) concentrations, rosuvastatin therapy, and residual vascular risk:analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention:an Intervention Trial Evaluating Rosuvastatin).Circulation, 4,9(6):635-642.
    [5] Zhao Y, Delaney JA, Quek RGW, et al.Cardiovascular disease, mortality risk, and healthcare costs by lipoprotein(a) levels according to low-density lipoprotein cholesterol levels in older high-risk adults.Clin Cardiol, 6,9(7):413-420.
    [6] Dai W, Long J, Cheng Y, et al.Elevated plasma lipoprotein(a) levels were associated with increased risk of cardiovascular events in Chinese patients with stable coronary artery disease.Sci Rep, 8,8(1):7726.
    [7] Hoefler G, Harnoncourt F, Paschke E, et al.Lipoprotein(a):A risk factor for myocardial infarction.Arteriosclerosis, 8,8(4):398-401.
    [8] Anderson TJ, Grégoire J, Pearson GJ, et al.2016 Canadian cardiovascular society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult.Can J Cardiol, 6,2(11):1263-1282.
    [9] Jang IK, Teamey GJ, MacNeill B, et al.In vivo characterization of coronary atherosclerotic plaque by use of optical co-herence tomography.Circulation, 5,1(12):1551-1555.
    [10] Guilbert JJ.The world health report 2002--reducing risks, promoting healthy life.Educ Health (Abingdon), 3,6(2):230.
    [11] Lopez AD, Murray CC.The global burden of disease 1990-2020.Nat Med, 8,4(11):1241-1243.
    [12] Naghavi M, Libby P, Falk E, et al.From vulnerable plaque to vulnerable patient.Circulation, 3,8(14):1664-1672.
    [13] Kamstrup PR, Tybjaerghansen A, Steffensen R, et al.Genetically elevated lipoprotein(a) and increased risk of myocardial infarction.JAMA, 9,1(22):2331-2339.
    [14] Zhou BY, Sun D, Wang C, et al.Plasma lipoprotein(a) concentration is associated with the coronary severity but not with events in stable coronary artery disease patients:A Chinese cohort study.Heart Lung Circ, 2018, DOI:10.1016/j.hlc.2018.05.190.
    [15] Tregouet DA, Konig IR, Erdmann J, et al.Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease.Nat Genet, 9,1(3):283-285.
    [16] Albers JJ, Slee A, O'Brien KD, et al.Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes:the AIM-HIGH trial (atherothrombosis intervention in metabolic syndrome with low HDL/high triglyceride and impact on global health outcomes).J AM Coll Cardiol, 3,2(17):1575-1579.
    [17] Cho JY, Jeong MH, Ahn Y, et al.High lipoprotein(a) levels are associated with long-term adverse outcomes in acute myocardial infarction patients in high Killip classes.Korean Circ J, 0,0(10):491-498.
    [18] Feng Z, Li HL, Bei WJ, et al.Association of lipoprotein(a) with long-term mortality following coronary angiography or percutaneous coronary intervention.Clin Cardiol, 7,0(9):674-678.
    [19] 费玲, 张军, 王长厚, 等.血清脂蛋白(a)水平与血管内超声斑块显像特征的关系.中华临床医师杂志, 4,8(5):888-890.
    [20] 李卫红.冠状动脉硬化易损斑块影响因素与急性冠状动脉综合征的关系.中华临床医师杂志, 3,7(12):169-171.
    [21] 覃群婷, 邓秀婷, 路文盛.脂蛋白(a)的研究进展.中国动脉硬化杂志, 8,6(2):194-200.
    [22] Pepke W, Eisenreich A, Jaster M, et al.Bivalirudin inhibits periprocedural platelet function and tissue factor expression of human smooth muscle cells.Cardiovasc Ther, 3,1(2):115-123.
    [23] Samarghandian S, Borji A, Delkhosh MB, et al.Safranal treatment improves hyperglycemia, hyperlipidemia and oxidative stress in streptozotocin-induced diabetic rats.J Pharm Sci, 3,6(2):352-362.
    [24] Buechler C, Ullrich H, Ritter M, et al.Lipoprotein(a) up-regulates the expression of the plasminogen activator inhibitor 2 in human blood monocytes.Blood, 1,7(4):981-986.
    [25] Leibundgut G, Scipione C, Yin H, et al.Determinants of binding of oxidized phospholipids on apolipoprotein A and lipoprotein(a).J Lipid Res, 3,4(10):815-830.
    [26] 李健斋, 王抒.低密度脂蛋白、脂蛋白(a)与冠心病.中华检验医学杂志, 9,2(1):5-8.
    [27] Niccoli G, Cin D, Scalone G, et al.Lipoprotein(a) is related to coronary atherosclerotic burden and a vulnerable plaque phenotype in angiographically obstructive coronary artery disease.Atherosclerosis, 6,6:214-220.
    Related
    Cited by
    Comments
    Comments
    分享到微博
    Submit
Get Citation

WANG Jun, LI Xing, JIA Lu, LI Xiaomei, LIU Fen, SHAN Chunfang, JIN Siyu, YANG Yining. Lipoprotein(a) level is independently correlated with vulnerable plaques in patients with coronary heart disease[J]. Editorial Office of Chinese Journal of Arteriosclerosis,2019,27(4):293-300.

Copy
Share
Article Metrics
  • Abstract:834
  • PDF: 790
  • HTML: 0
  • Cited by: 0
History
  • Received:December 19,2018
  • Revised:January 21,2019
  • Online: April 08,2019
Article QR Code